Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12779/6709
Title: Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Authors: Ranganath LR
Milan AM
Hughes AT
Dutton JJ
Fitzgerald R
Briggs MC
Bygott H
Psarelli EE
Cox TF
Gallagher JA
Jarvis JC
van Kan C
Hall AK
Laan D
Olsson B
Szamosi J
Rudebeck M
Kullenberg T
Cronlund A
Svensson L
Junestrand C
Ayoob H
Timmis OG
Sireau N
Le Quan Sang KH
Genovese F
Braconi, Daniela 
Santucci, Annalisa 
Nemethova M
Zatkova A
McCaffrey J
Christensen P
Ross G
Imrich R
Rovensky J
Keywords: Arthritis; Osteoarthritis; Spondyloarthritis
Issue Date: 2016
Project: None 
Journal: ANNALS OF THE RHEUMATIC DISEASES
Abstract: 
BACKGROUND: Alkaptonuria (AKU) is a serious genetic disease characterised by premature spondyloarthropathy. Homogentisate-lowering therapy is being investigated for AKU. Nitisinone decreases homogentisic acid (HGA) in AKU but the dose-response relationship has not been previously studied. METHODS: Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1) was an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study. The primary objective was to investigate the effect of different doses of nitisinone once daily on 24-h urinary HGA excretion (u-HGA24) in patients with AKU after 4 weeks of treatment. Forty patients were randomised into five groups of eight patients each, with groups receiving no treatment or 1 mg, 2 mg, 4 mg and 8 mg of nitisinone. FINDINGS: A clear dose-response relationship was observed between nitisinone and the urinary excretion of HGA. At 4 weeks, the adjusted geometric mean u-HGA24 was 31.53 mmol, 3.26 mmol, 1.44 mmol, 0.57 mmol and 0.15 mmol for the no treatment or 1 mg, 2 mg, 4 mg and 8 mg doses, respectively. For the most efficacious dose, 8 mg daily, this corresponds to a mean reduction of u-HGA24 of 98.8% compared with baseline. An increase in tyrosine levels was seen at all doses but the dose-response relationship was less clear than the effect on HGA. Despite tyrosinaemia, there were no safety concerns and no serious adverse events were reported over the 4 weeks of nitisinone therapy. CONCLUSIONS: In this study in patients with AKU, nitisinone therapy decreased urinary HGA excretion to low levels in a dose-dependent manner and was well tolerated within the studied dose range. TRIAL REGISTRATION NUMBER: EudraCT number: 2012-005340-24. Registered at ClinicalTrials.gov: NCTO1828463.
Description: 
112838
URI: http://hdl.handle.net/20.500.12779/6709
ISSN: 0003-4967
DOI: 10.1136/annrheumdis-2014-206033
Appears in Collections:Publications

Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.